Literature DB >> 20978390

Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.

Birgit Grund1, Caroline Sabin.   

Abstract

PURPOSE OF REVIEW: We discuss two data analysis issues for studies that use binary clinical outcomes (whether or not an event occurred): the choice of an appropriate scale and transformation when biomarkers are evaluated as explanatory factors in logistic regression and assessing the ability of biomarkers to improve prediction accuracy for event risk. RECENT
FINDINGS: Biomarkers with skewed distributions should be transformed before they are included as continuous covariates in logistic regression models. The utility of new biomarkers may be assessed by measuring the improvement in predicting event risk after adding the biomarkers to an existing model. The area under the receiver operating characteristic (ROC) curve (C-statistic) is often cited; it was developed for a different purpose, however, and may not address the clinically relevant questions. Measures of risk reclassification and risk prediction accuracy may be more appropriate.
SUMMARY: The appropriate analysis of biomarkers depends on the research question. Odds ratios obtained from logistic regression describe associations of biomarkers with clinical events; failure to accurately transform the markers, however, may result in misleading estimates. Although the C-statistic is often used to assess the ability of new biomarkers to improve the prediction of event risk, other measures may be more suitable.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20978390      PMCID: PMC3157029          DOI: 10.1097/COH.0b013e32833ed742

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  27 in total

1.  The limitations of risk factors as prognostic tools.

Authors:  James H Ware
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

2.  Integrating the predictiveness of a marker with its performance as a classifier.

Authors:  Margaret S Pepe; Ziding Feng; Ying Huang; Gary Longton; Ross Prentice; Ian M Thompson; Yingye Zheng
Journal:  Am J Epidemiol       Date:  2007-11-02       Impact factor: 4.897

3.  The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929).

Authors:  Sander Greenland
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

4.  Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Stat Med       Date:  2008-01-30       Impact factor: 2.373

Review 5.  Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease.

Authors:  Donald M Lloyd-Jones; Kiang Liu; Lu Tian; Philip Greenland
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

6.  The effect of including C-reactive protein in cardiovascular risk prediction models for women.

Authors:  Nancy R Cook; Julie E Buring; Paul M Ridker
Journal:  Ann Intern Med       Date:  2006-07-04       Impact factor: 25.391

7.  Multiple biomarkers for the prediction of first major cardiovascular events and death.

Authors:  Thomas J Wang; Philimon Gona; Martin G Larson; Geoffrey H Tofler; Daniel Levy; Christopher Newton-Cheh; Paul F Jacques; Nader Rifai; Jacob Selhub; Sander J Robins; Emelia J Benjamin; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

8.  Use and misuse of the receiver operating characteristic curve in risk prediction.

Authors:  Nancy R Cook
Journal:  Circulation       Date:  2007-02-20       Impact factor: 29.690

9.  Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

Authors:  Paul M Ridker; Julie E Buring; Nader Rifai; Nancy R Cook
Journal:  JAMA       Date:  2007-02-14       Impact factor: 56.272

10.  Inflammatory and coagulation biomarkers and mortality in patients with HIV infection.

Authors:  Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton
Journal:  PLoS Med       Date:  2008-10-21       Impact factor: 11.069

View more
  36 in total

1.  Towards early monitoring of chemotherapy-induced drug resistance based on single cell metabolomics: Combining single-probe mass spectrometry with machine learning.

Authors:  Renmeng Liu; Mei Sun; Genwei Zhang; Yunpeng Lan; Zhibo Yang
Journal:  Anal Chim Acta       Date:  2019-09-25       Impact factor: 6.558

2.  Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development.

Authors:  George Poste; David P Carbone; David R Parkinson; Jaap Verweij; Stephen M Hewitt; J Milburn Jessup
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

3.  Serum levels of lipid metabolites in age-related macular degeneration.

Authors:  Tivadar Orban; William M Johnson; Zhiqian Dong; Tadao Maeda; Akiko Maeda; Tsutomu Sakai; Hiroshi Tsuneoka; John J Mieyal; Krzysztof Palczewski
Journal:  FASEB J       Date:  2015-07-17       Impact factor: 5.191

4.  Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.

Authors:  A J Tafur; G Dale; M Cherry; J D Wren; A S Mansfield; P Comp; S Rathbun; J A Stoner
Journal:  Thromb Res       Date:  2015-10-08       Impact factor: 3.944

5.  Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population.

Authors:  Hui-Chen Wu; Hwai-I Yang; Qiao Wang; Chien-Jen Chen; Regina M Santella
Journal:  Carcinogenesis       Date:  2017-10-01       Impact factor: 4.944

6.  Reclassification of risk of death with the knowledge of D-dimer in a cohort of treated HIV-infected individuals.

Authors:  Amit C Achhra; Janaki Amin; Caroline Sabin; Haitao Chu; David Dunn; Lewis H Kuller; Joseph A Kovacs; David A Cooper; Sean Emery; Matthew G Law
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

7.  Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: The SMART body composition substudy.

Authors:  Jennifer Hoy; Birgit Grund; Mollie Roediger; Kristine E Ensrud; Indira Brar; Robert Colebunders; Nathalie De Castro; Margaret Johnson; Anjali Sharma; Andrew Carr
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

8.  A new approach to define acute kidney injury in term newborns with hypoxic ischemic encephalopathy.

Authors:  Charu Gupta; An N Massaro; Patricio E Ray
Journal:  Pediatr Nephrol       Date:  2016-02-08       Impact factor: 3.714

9.  Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease.

Authors:  Jonathan I Goldstein; Douglas J Kominsky; Nicole Jacobson; Brittelle Bowers; Kirsten Regalia; Gregory L Austin; Melinda Yousefi; Michael T Falta; Andrew P Fontenot; Mark E Gerich; Lucy Golden-Mason; Sean P Colgan
Journal:  Gastroenterology       Date:  2011-04-07       Impact factor: 22.682

10.  Variable neuroendocrine-immune dysfunction in individuals with unfavorable outcome after severe traumatic brain injury.

Authors:  M Santarsieri; R G Kumar; P M Kochanek; S Berga; A K Wagner
Journal:  Brain Behav Immun       Date:  2014-09-16       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.